Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | METAP2 | P50579 | 1/20 | 0.65 |
| ▸ | METAP1 | P53582 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butanedione SCHEMBL5530736 | 0.98 | LMNA (0.63) | LMNAMETAP2METAP1HDAC6KDM4E | |
| Hydrochloric Acid SCHEMBL2563239 | 0.98 | LMNA (0.63) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL19733333 | 0.87 | LMNA (0.51) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL28459061 | 0.86 | LMNA (0.69) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL2839930 | 0.85 | LMNA (0.60) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL3415803 | 0.84 | LMNA (0.71) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL7364217 | 0.83 | L3MBTL1 (0.62) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL3454629 | 0.83 | LMNA (0.61) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL111242 | 0.83 | LMNA (0.65) | LMNAMETAP2METAP1HDAC6KDM4E | |
| SCHEMBL10356985 | 0.83 | LMNA (0.65) | LMNAMETAP2METAP1HDAC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292492-A | Method for preparing clioquinol and diiodoquinol by one-pot method | 常州工程职业技术学院 | 2021-08-24 | — | — | CN | claimed |
| CN-111018779-A | 2- (3-isoquinolyl) -ethyl propionate derivative and synthetic method thereof | 中国科学院大连化学物理研究所 | 2020-04-17 | — | — | CN | claimed |
| EP-2935198-B1 | METHOD FOR STABILISING POLYMERISABLE COMPOUNDS | BASF SE (DE) | 2019-06-05 | — | — | EP | claimed |
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | claimed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| US-9206109-B2 | Method of stabilizing polymerizable compounds | BASF SE (DE) | 2015-12-08 | — | — | US | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| EP-2935198-A2 | METHOD FOR STABILISING POLYMERISABLE COMPOUNDS | BASF SE (DE) | 2015-10-28 | — | — | EP | claimed |
| US-20140228571-A1 | METHOD OF STABILIZING POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2014-08-14 | — | — | US | claimed |
| WO-2014095437-A2 | METHOD FOR STABILISING POLYMERISABLE COMPOUNDS | BASF SE (DE) | 2014-06-26 | — | — | WO | claimed |
| EP-0649425-B1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | UPJOHN CO (US) | 1999-03-10 | — | — | EP | claimed |
| US-5597816-A | Pyrazoloazepino substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1997-01-28 | — | — | US | claimed |
| EP-0271798-B1 | O-SUBSTITUTED TETRAHYDROPYRIDINE OXIME CHOLINERGIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-04-07 | — | — | EP | claimed |
| EP-0368866-A1 | ARYL SUBSTITUTED NAPHTHALENE, BENZOXEPINE, BENZAZEPINE, BENZOCYCLOHEPTENE DERIVATIVES | SCHERING CORPORATION (US) | 1990-05-23 | — | — | EP | claimed |
| WO-1988008836-A2 | ARYL SUBSTITUTED NAPHTHALENE, BENZOXEPINE, BENZAZEPINE, BENZOCYCLOHEPTENE DERIVATIVES | SCHERING CORPORATION (US) | 1988-11-17 | — | — | WO | claimed |
| EP-0145506-B1 | ELIMINATION OF DEFECTS IN CYSTEINE-SENSITIZED EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| US-4710508-A | ANALGESICS | WARNER-LAMBERT COMPANY (US) | 1987-12-01 | — | — | US | claimed |
| EP-0145506-A2 | Elimination of defects in cysteine-sensitized emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-06-19 | — | — | EP | claimed |
| US-4514492-A | Elimination of defects in cysteine-sensitized emulsions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | claimed |
| US-4225679-A | Floral foam product and method of producing the same which incorporates a flower preservative and a bacteriocide | PENNOCK, VILLAMIL AND PILATO INC. (US) | 1980-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228571-A1 | METHOD OF STABILIZING POLYMERIZABLE COMPOUNDS | AOC1, AOC2, AOC3 | LMNA 545/4885METAP2 3354/4885METAP1 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.